ES2664951T5 - Composiciones que comprenden glicosaminoglicanos de baja viscosidad y uso de dicha composición en terapia de cistitis crónica - Google Patents

Composiciones que comprenden glicosaminoglicanos de baja viscosidad y uso de dicha composición en terapia de cistitis crónica Download PDF

Info

Publication number
ES2664951T5
ES2664951T5 ES07729534T ES07729534T ES2664951T5 ES 2664951 T5 ES2664951 T5 ES 2664951T5 ES 07729534 T ES07729534 T ES 07729534T ES 07729534 T ES07729534 T ES 07729534T ES 2664951 T5 ES2664951 T5 ES 2664951T5
Authority
ES
Spain
Prior art keywords
solution
chondroitin sulfate
viscosity
composition
purified water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07729534T
Other languages
English (en)
Spanish (es)
Other versions
ES2664951T3 (es
Inventor
Giorgio Zoppetti
Nadia Puppini
Marco Pizzutti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altergon SA
Original Assignee
Altergon SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38617962&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2664951(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Altergon SA filed Critical Altergon SA
Application granted granted Critical
Publication of ES2664951T3 publication Critical patent/ES2664951T3/es
Publication of ES2664951T5 publication Critical patent/ES2664951T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
ES07729534T 2006-05-26 2007-05-25 Composiciones que comprenden glicosaminoglicanos de baja viscosidad y uso de dicha composición en terapia de cistitis crónica Active ES2664951T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI20061030 2006-05-26
IT001030A ITMI20061030A1 (it) 2006-05-26 2006-05-26 Nuova composizione comprendente glicosamminoglicani a viscosita' controllata e uso di tale composizione nella terapuia della cistite cronica
PCT/EP2007/055107 WO2007138014A1 (en) 2006-05-26 2007-05-25 Compositions comprising glycosaminoglycans of low viscosity and use of said composition in therapy of chronic cystitis

Publications (2)

Publication Number Publication Date
ES2664951T3 ES2664951T3 (es) 2018-04-24
ES2664951T5 true ES2664951T5 (es) 2023-09-27

Family

ID=38617962

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07729534T Active ES2664951T5 (es) 2006-05-26 2007-05-25 Composiciones que comprenden glicosaminoglicanos de baja viscosidad y uso de dicha composición en terapia de cistitis crónica

Country Status (12)

Country Link
US (1) US8252770B2 (ja)
EP (1) EP2034956B2 (ja)
JP (1) JP5177446B2 (ja)
CA (1) CA2653369C (ja)
DK (1) DK2034956T4 (ja)
ES (1) ES2664951T5 (ja)
FI (1) FI2034956T4 (ja)
HU (1) HUE037542T2 (ja)
IT (1) ITMI20061030A1 (ja)
PL (1) PL2034956T5 (ja)
TR (1) TR201808687T4 (ja)
WO (1) WO2007138014A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1402382B1 (it) 2010-09-09 2013-09-04 Ibsa Inst Biochimique Sa Complessi cooperativi ibridi di acido ialuronico
ITPD20120098A1 (it) 2012-03-30 2013-10-01 Fidia Farmaceutici "nuove formulazioni faramaceutiche contenenti condroitin solfato e derivati dell'acido ialuronico"
ITMI20130075A1 (it) 2013-01-21 2014-07-22 Altergon Sa Combinazione orale per la prevenzione e il trattamento di patologie vescicali, pelviche e dell¿apparato uro-genitale
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
WO2014142938A1 (en) * 2013-03-15 2014-09-18 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
KR20240042200A (ko) 2013-09-11 2024-04-01 이글 바이오로직스 인코퍼레이티드 점도저하제를 함유하는 액체 단백질 제형
KR102497368B1 (ko) * 2014-10-01 2023-02-10 이글 바이올로직스 인코포레이티드 점도-저하제를 함유하는 폴리삭카라이드 및 핵산 제형
MA46426A (fr) * 2016-09-16 2019-07-24 Glycologix Llc Biomatériaux à base de glycosaminoglycanes sulfatés utilisés en tant que mimétiques de protéoglycanes
ES2775673T3 (es) * 2017-05-12 2020-07-27 Farco Gmbh Composición para el tratamiento de enfermedades inflamatorias del tracto urogenital que contiene sulfato de condonita (4,5 mg/ml), ácido hialurónico (16 mg/ml) y tampón de fosfato (pH 6,1 a 7,9) con mayor estabilidad de almacenamiento para tratar la cistitis
ES2769059T3 (es) 2017-05-12 2020-06-24 Farco Gmbh Composición de instilación de la vejiga que contiene sulfato de condonitina (20 mg/ml), ácido hialurónico (16 mg/ml) y buffer de fosfato (pH 6,1 a 7,9) con mayor estabilidad de almacenamiento para el tratamiento de la cistitis
CN114748635A (zh) * 2020-12-25 2022-07-15 姜秉均 含有疏水性物质的纳米组成物及其制备方法与用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486416A (en) † 1981-03-02 1984-12-04 Soll David B Protection of human and animal cells subject to exposure to trauma
US4971955A (en) 1981-03-02 1990-11-20 Soll David B Protection of human and animal cells during surgical trauma
AU555747B2 (en) * 1983-08-09 1986-10-09 Cilco Inc. Chondroitin sulfate and sodium hyaluronate composition
JPS6147418A (ja) * 1984-08-13 1986-03-07 Seikagaku Kogyo Co Ltd ヒアルロン酸含有胃粘膜保護剤
DE69017559T3 (de) * 1989-07-24 2002-06-06 Allergan Pharmaceuticals Irela Stabile Lösung von Hyaluronat in einem isotonen Salzmilieu.
US5627162A (en) 1990-01-11 1997-05-06 Gwon; Arlene E. Methods and means for control of proliferation of remnant cells following surgery
JPH0662425B2 (ja) * 1992-12-02 1994-08-17 生化学工業株式会社 ヒアルロン酸含有血中脂質低下剤
US5952006A (en) 1995-09-29 1999-09-14 L.A.M. Pharmaceuticals, Llc Drug preparations for treating impotency
US20020025921A1 (en) 1999-07-26 2002-02-28 Petito George D. Composition and method for growing, protecting, and healing tissues and cells
US6984667B2 (en) 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
CA2347110C (en) 1998-10-22 2008-08-26 Bioniche Life Sciences Inc. A method for preventing, reducing, and treating radiation cystitis using hyaluronic acid
CA2269260C (en) 1999-04-16 2002-12-31 Stellar International Inc. Treatment of cystitis with chondroitin sulfate
US6083933A (en) 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
AU8136801A (en) 2000-07-31 2002-02-13 Dermal Res Lab Inc Methods of preventing or treating diseases and conditions using complex carbohydrates
JP2003201257A (ja) * 2001-11-05 2003-07-18 Seikagaku Kogyo Co Ltd 上皮膨隆用の医療用組成物
US6780841B2 (en) 2001-11-13 2004-08-24 Biocell Technology, Llc Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type II and method of making same
MXPA01011542A (es) 2001-11-13 2003-05-22 Alcon Inc Regeneracion del cartilago articular da°ado por la osteoartritis de grado i y ii, mediante la aplicacion intra-articular de una mezcla de hialuronato de sodio y de condroitin sulfato en un vehiculo de gel.
ATE525076T1 (de) * 2002-10-16 2011-10-15 Arthrodynamic Technologies Animal Health Division Inc Behandlung von traumatischer synovitis und geschädigtem gelenkknorpel
JP2004137183A (ja) * 2002-10-17 2004-05-13 Kotobuki Seiyaku Kk グリコサミノグリカン又はその塩を含む経口投与用医薬品、健康食品又は栄養薬品組成物
JP4143387B2 (ja) * 2002-11-21 2008-09-03 株式会社アセロラフーズ 健康食品
US20040161476A1 (en) * 2003-02-19 2004-08-19 Hahn Sungtack Samuel Cystitis treatment with high dose chondroitin sulfate
JP2004359554A (ja) * 2003-06-02 2004-12-24 Spirulina Biological Lab Ltd 老化防止剤及び皮膚外用剤
WO2006035969A1 (ja) 2004-09-28 2006-04-06 Senju Pharmaceutical Co., Ltd. キサンタンガムおよびアミノ酸を含有する眼科用組成物

Also Published As

Publication number Publication date
DK2034956T3 (en) 2018-05-22
US8252770B2 (en) 2012-08-28
PL2034956T5 (pl) 2023-08-07
DK2034956T4 (da) 2023-07-24
JP5177446B2 (ja) 2013-04-03
EP2034956B1 (en) 2018-03-21
US20090181924A1 (en) 2009-07-16
ITMI20061030A1 (it) 2007-11-27
TR201808687T4 (tr) 2018-07-23
WO2007138014A1 (en) 2007-12-06
ES2664951T3 (es) 2018-04-24
FI2034956T4 (fi) 2023-08-31
EP2034956A1 (en) 2009-03-18
EP2034956B2 (en) 2023-06-28
JP2009538287A (ja) 2009-11-05
PL2034956T3 (pl) 2018-08-31
HUE037542T2 (hu) 2018-09-28
CA2653369C (en) 2015-11-17
CA2653369A1 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
ES2664951T5 (es) Composiciones que comprenden glicosaminoglicanos de baja viscosidad y uso de dicha composición en terapia de cistitis crónica
ES2217741T3 (es) Formulaciones de dextrano que sirven para tratar transtornos articulares inflamatorios.
JP5919597B2 (ja) デオキシコール酸およびその塩類の製剤
JP2008542324A (ja) 医療用デバイスおよび医薬製剤において有用な粘膜付着性キシログルカン含有製剤
WO2008014685A1 (fr) Formulation contenant du tréhalose à des fins d'injection intraarticulaire
ES2373867T3 (es) Composiciones y procedimientos para el suministro de agentes anticancerosos.
CZ290534B6 (cs) Kombinační prostředky pro léčení bazocelulárního karcinomu nebo aktinických keratóz
ES2475790T3 (es) Composición oft�lmica basada en ácido lactobi�nico útil para reducir el edema de córnea e inflamación
ES2891548T3 (es) Composiciones que contienen silicato y métodos de tratamiento
JP2008525504A5 (ja)
KR20100017183A (ko) 체온 저하 억제제
JP6595717B2 (ja) 骨関節炎治療のための親水化されたスルファサラジンおよびヒアルロン酸を含む組成物およびその製造方法
US8367636B2 (en) Composition based on salts of hyaluronic acid for treating epithelial lesions
RU2008126108A (ru) Фармацевтическая композиция для лечения остеоартрита, содержащая клодроновую кислоту и гиалуроновую кислоту
WO2008014686A1 (fr) Formulation contenant de l'héparine de faible masse moléculaire à des fins d'injection intraarticulaire
JP2016147890A (ja) デオキシコール酸およびその塩類の製剤
EP1884241B1 (en) A oral preparation comprising dyclonine hydrochloride
JP6356329B2 (ja) デオキシコール酸およびその塩類の製剤
JP6594486B2 (ja) デオキシコール酸およびその塩類の製剤
ES2775673T3 (es) Composición para el tratamiento de enfermedades inflamatorias del tracto urogenital que contiene sulfato de condonita (4,5 mg/ml), ácido hialurónico (16 mg/ml) y tampón de fosfato (pH 6,1 a 7,9) con mayor estabilidad de almacenamiento para tratar la cistitis
JPH1179984A (ja) 口腔・咽喉疾患用液剤
KR20230140488A (ko) 장 정결용 조성물
ES2367454T3 (es) Preparación farmacéutica para el tratamiento de enfermedades inflamatorias del tracto genitourinario.
TWI373338B (en) Pharmaceutical composition containing transcription factor decoys and their preparation method and applications
JP2007230990A (ja) メニエール病治療薬